var data={"title":"Chlorambucil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Chlorambucil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5866?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=chlorambucil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Chlorambucil: Patient drug information&quot;</a> and <a href=\"topic.htm?path=chlorambucil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Chlorambucil: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708649\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Chlorambucil can severely suppress bone marrow function. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fertility effects: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149339\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Leukeran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149340\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Leukeran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149382\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Alkylating Agent;</li>\n      <li>\n        Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149343\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reduce initial dose if full-dose radiation or myelotoxic drugs have been administered within the last month. With bone marrow lymphocytic infiltration involvement (in CLL, Hodgkin lymphoma, or NHL), the maximum dose is 0.1 mg/kg/day. While short treatment courses are preferred, if maintenance therapy is required, the maximum dose is 0.1 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL):</b> Oral: 0.1 mg/kg/day for 3 to 6 weeks <b>or</b> 0.4 mg/kg pulsed doses administered intermittently, biweekly, or monthly (increased by 0.1 mg/kg/dose until response/toxicity observed)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CLL (off-label dosing): </i>0.4 mg/kg day 1 every 2 weeks; if tolerated may increase by 0.1 mg/kg with each treatment course to a maximum dose of 0.8 mg/kg and maximum of 24 cycles (Eichhorst 2009) <b>or</b> 30 mg/m<sup>2</sup> day 1 every 2 weeks (in combination with prednisone) (Raphael 1991) <b>or</b> 40 mg/m<sup>2</sup> day 1 every 4 weeks until disease progression or complete remission or response plateau for up to a maximum of 12 cycles (Rai 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CLL in previously untreated patients (off-label combinations):</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>In combination with obinutuzumab: </i>0.5 mg/kg on days 1 and 15 every 28 days for 6 cycles (Goede 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>In combination with ofatumumab: </i>10 mg/m<sup>2</sup> once daily for 7 days (days 1 to 7) every 28 days for a minimum of 3 cycles and up to 12 cycles or best response (clinical response that did not improve after 3 additional cycles); if necessary, reduce dose to 7.5 mg/m<sup>2</sup>/day and then to 5 mg/m<sup>2</sup>/day for hematologic toxicity (Hillmen 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma:</b> Oral: 0.2 mg/kg/day for 3 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphomas (NHL):</b> Oral: 0.1 mg/kg/day for 3 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m macroglobulinemia (off-label use):</b> Oral: 0.1 mg/kg/day (continuously) for at least 6 months <b>or</b> 0.3 mg/kg/day for 7 days every 6 weeks for at least 6 months (Kyle 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149362\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=chlorambucil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Chlorambucil: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Nephrotic syndrome, steroid sensitive (off-label use):</b> Oral: 0.2 mg/kg once daily for ~8 weeks (Hodson 2010)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149344\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">Refer to adult dosing. Begin at the lower end of dosing range(s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5526979\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of unchanged chlorambucil and active metabolite (phenylacetic acid mustard) is minimal and renal impairment is not likely to affect elimination. The following adjustments have been recommended: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: No adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 to 50 mL/minute: Administer 75% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peritoneal dialysis (PD): Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kintzel 1995: Based on the pharmacokinetics, dosage adjustment is not indicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5527179\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Chlorambucil undergoes extensive hepatic metabolism. Although dosage reduction should be considered in patients with hepatic impairment, there are no dosage adjustments provided in the manufacturer's labeling (data is insufficient).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20397633\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:</i> Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012). <b>Note:</b> The manufacturer recommends the maximum dose should not exceed 0.1 mg/kg/day if maintenance therapy is required and with bone marrow infiltration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4412251\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Skin reactions: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hematologic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">WBC or platelets below normal: Reduce dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Severely depressed WBC or platelet counts: Discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Persistently low neutrophil or platelet counts or peripheral lymphocytosis: May be suggestive of bone marrow infiltration; if infiltration confirmed, do not exceed 0.1 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Concurrent or within 4 weeks (before or after) of chemotherapy/radiotherapy: Initiate treatment cautiously; reduce dose; monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149314\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leukeran: 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149299\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149318\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered as a single daily dose. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130944\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149317\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia:</b> Management of chronic lymphocytic leukemia (CLL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphomas:</b> Management of Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475344\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Nephrotic syndrome, steroid sensitive (pediatrics); Waldenstr&ouml;m macroglobulinemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149390\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chlorambucil may be confused with Chloromycetin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leukeran may be confused with Alkeran, leucovorin, Leukine, Myleran</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149306\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Drug fever, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Dermatologic: Allergic skin reaction, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Amenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Gastrointestinal: Diarrhea (infrequent), nausea (infrequent), oral mucosa ulcer (infrequent), vomiting (infrequent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Genitourinary: Azoospermia, cystitis (sterile), infertility</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, bone marrow depression, bone marrow failure (irreversible), leukemia (secondary), leukopenia, lymphocytopenia, malignant neoplasm (secondary), neutropenia (onset: 3 weeks; recovery: 10 days after last dose), pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Hepatic: Hepatotoxicity, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Respiratory: Interstitial pneumonitis, pulmonary fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">1%, postmarketing, and/or case reports: Agitation, ataxia, confusion, erythema multiforme, flaccid paralysis, seizure (focal/generalized), hallucination, muscle twitching, myoclonus, SIADH (syndrome of inappropriate antidiuretic hormone secretion), Stevens-Johnson syndrome, toxic epidermal necrolysis, tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149322\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to chlorambucil or any component of the formulation; hypersensitivity to other alkylating agents (may have cross-hypersensitivity); prior (demonstrated) resistance to chlorambucil</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Use within 4 weeks of a full course of radiation or chemotherapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149303\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: <b>[U.S. Boxed Warning]: May cause severe bone marrow suppression;</b> neutropenia may be severe. Reduce initial dosage if patient has received myelosuppressive or radiation therapy within the previous 4 weeks, or has a depressed baseline leukocyte or platelet count. Irreversible bone marrow damage may occur with total doses approaching 6.5 mg/kg. Progressive lymphopenia may develop (recovery is generally rapid after discontinuation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fertility effects: <b>[U.S. Boxed Warning]: Affects human fertility;  probably mutagenic and teratogenic as well;</b> chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males) and amenorrhea (in females) have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary malignancy: <b>[U.S. Boxed Warning]: Carcinogenic;</b> acute myelocytic leukemia and secondary malignancies may be associated with chronic therapy. Duration of treatment and higher cumulative doses are associated with a higher risk for development of leukemia. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Have been observed with use; patients with a history of nephrotic syndrome and high pulse doses are at higher risk of seizures. Use with caution in patients with a history of seizure disorder or head trauma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Rare instances of severe skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported; discontinue promptly if skin reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Chlorambucil is primarily metabolized in the liver.  Dosage reductions should be considered in patients with hepatic impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vaccines: Avoid administration of live vaccines to immunocompromised patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299014\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149308\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9240&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13645942\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption is decreased when administered with food. Management: Administer preferably on an empty stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149310\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149325\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have demonstrated teratogenicity. Chlorambucil crosses the human placenta. Following exposure during the first trimester, case reports have noted adverse renal effects (unilateral agenesis). Women of childbearing potential should avoid becoming pregnant while receiving treatment. <b>[U.S. Boxed Warning]: Affects human fertility; probably mutagenic and teratogenic as well</b>; chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males) and amenorrhea (in females) have been observed. Fibrosis, vasculitis and depletion of primordial follicles have been noted on autopsy of the ovaries. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4412250\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if chlorambucil is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue chlorambucil or to discontinue breast-feeding should take into account the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149312\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, CBC with differential (weekly, with WBC monitored twice weekly during the first 3 to 6 weeks of treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149302\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alkylating agent; interferes with DNA replication and RNA transcription by alkylation and cross-linking the strands of DNA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149321\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and complete (&gt;70%) from GI tract; reduced with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~99%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (extensively); primarily to active metabolite, phenylacetic acid mustard</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~1.5 hours; Phenylacetic acid mustard: ~1.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Within 1 hour; Phenylacetic acid mustard: Within 1.9 &plusmn; 0.7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~20% to 60% within 24 hours, primarily as inactive metabolites, &lt;1% as unchanged drug or phenylacetic acid mustard)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149324\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Leukeran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (25): $729.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149326\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Chloraminophene (FR);</li>\n      <li>Clokeran (LK);</li>\n      <li>Leukeran (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Leykeran (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichhorst BF, Busch R, Stilgenbauer S, et al, &ldquo;First-Line Therapy With Fludarabine Compared With Chlorambucil Does Not Result in a Major Benefit for Elderly Patients With Advanced Chronic Lymphocytic Leukemia,&rdquo; <i>Blood</i>, 2009, 114(16):3382-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/19605849/pubmed\" target=\"_blank\" id=\"19605849\">19605849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>N Engl J Med.</i> 2014;370(12):1101-1110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/24401022/pubmed\" target=\"_blank\" id=\"24401022\">24401022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet.</i> 2015;385(9980):1873-1883.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/25882396/pubmed\" target=\"_blank\" id=\"25882396\">25882396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18254005\"></a>Hodson EM, Willis NS, and Craig JC, &ldquo;Non-Corticosteroid Treatment for Nephrotic Syndrome in Children (Review),&rdquo; <i>Cochrane Database Syst Rev</i>, 2010, (4):CD002290.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/18254005/pubmed\" target=\"_blank\" id=\"18254005\">18254005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10792277\"></a>Kyle RA, Greipp PR, Gertz MA, et al, &ldquo;Waldenstr&ouml;m's Macroglobulinemia: A Prospective Study Comparing Daily With Intermittent Oral Chlorambucil,&rdquo; <i>Br J Haematol</i>, 2000, 108(4):737-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/10792277/pubmed\" target=\"_blank\" id=\"10792277\">10792277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leukeran (chlorambucil) (prescribing information). Mason, OH: Prasco Laboratories; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leukeran (chlorambucil) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rai KR, Peterson BL, Appelbaum FR, et al, &ldquo;Fludarabine Compared With Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia,&rdquo; <i>N Engl J Med</i>, 2000, 343(24):1750-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/11114313/pubmed\" target=\"_blank\" id=\"11114313\">11114313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raphael B, Andersen JW, Silber R, et al, &ldquo;Comparison of Chlorambucil and Prednisone Versus Cyclophosphamide, Vincristine, and Prednisone as Initial Treatment for Chronic Lymphocytic Leukemia: Long-Term Follow-Up of an Eastern Cooperative Oncology Group Randomized Clinical Trial,&rdquo; <i>J Clin Oncol</i>, 1991, 9(5):770-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/2016618/pubmed\" target=\"_blank\" id=\"2016618\">2016618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson RF, Nahata MC, Mahan JD, &ldquo;Management of Nephrotic Syndrome in Children,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(8):1021-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/12921248/pubmed\" target=\"_blank\" id=\"12921248\">12921248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Selby P, Patel P, Milan S, et al, &ldquo;ChIVPP Combination Chemotherapy for Hodgkin's Disease: Long-Term Results,&rdquo; <i>Br J Cancer</i>, 1990, 62(2):279-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/2386744 /pubmed\" target=\"_blank\" id=\"2386744 \">2386744 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    The International ChIVPP Treatment Group, &ldquo;ChIVPP Therapy for Hodgkin&rsquo;s Disease: Experience of 960 Patients,&rdquo; <i>Ann Oncol</i>, 1995, 6(2):167-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/7786824/pubmed\" target=\"_blank\" id=\"7786824\">7786824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vose JM, Bierman PJ, Anderson JR, et al, &ldquo;CHLVPP Chemotherapy With Involved-Field Irradiation for Hodgkin&rsquo;s Disease: Favorable Results With Acceptable Toxicity,&rdquo; <i>J Clin Oncol</i>, 1991, 9(8):1421-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorambucil-drug-information/abstract-text/2072145/pubmed\" target=\"_blank\" id=\"2072145\">2072145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner AM, Brunet S, Puig J, et al, &ldquo; Chlorambucil-Induced Inappropriate Antidiuresis in Man With Chronic Lymphocytic Leukemia,&rdquo; <i>Ann Hemat</i>, 1999, 78(1):37-8.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9240 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708649\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F149339\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F149340\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F149382\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F149343\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F149362\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F149344\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5526979\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5527179\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20397633\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F4412251\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F149314\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F149299\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F149318\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130944\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F149317\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475344\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F149390\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F149306\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149322\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F149303\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299014\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F149308\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13645942\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F149310\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F149325\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4412250\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F149312\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F149302\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F149321\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F149324\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F149326\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9240|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=chlorambucil-patient-drug-information\" class=\"drug drug_patient\">Chlorambucil: Patient drug information</a></li><li><a href=\"topic.htm?path=chlorambucil-pediatric-drug-information\" class=\"drug drug_pediatric\">Chlorambucil: Pediatric drug information</a></li></ul></div></div>","javascript":null}